{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/leg-ulcer-venous/prescribing-information/co-trimoxazole/","result":{"pageContext":{"chapter":{"id":"1cf75cbb-8bc4-58cc-9a1b-11516db5ad2c","slug":"co-trimoxazole","fullItemName":"Co-trimoxazole","depth":2,"htmlHeader":"<!-- begin field aa06e8a3-d713-4ab2-82cb-aaa800f0c3a4 --><h2>Co-trimoxazole</h2><!-- end field aa06e8a3-d713-4ab2-82cb-aaa800f0c3a4 -->","summary":"","htmlStringContent":"<!-- begin item c953dee6-7ff4-4e25-bd8a-aa9000d60785 --><!-- end item c953dee6-7ff4-4e25-bd8a-aa9000d60785 -->","topic":{"id":"627b2b3c-014b-5543-8f89-0f3ffa6344ad","topicId":"4c5db985-9544-48b2-8c54-8915ec210739","topicName":"Leg ulcer - venous","slug":"leg-ulcer-venous","lastRevised":"Last revised in January 2021","chapters":[{"id":"01818c5e-efb9-59c4-b339-08b834294232","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"313e84c5-8bc7-5150-826a-467ea7252acd","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"2597db24-8ec5-54d4-86ad-8082be50f4f6","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"38f24092-0019-582d-86bf-d1f61bccde1d","slug":"changes","fullItemName":"Changes"},{"id":"cdc15e74-0503-53a5-a4be-c53ec4e20898","slug":"update","fullItemName":"Update"}]},{"id":"73d0cf59-f9c0-5785-8c74-e756826d5d1e","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"64b11689-d52a-560f-8d9b-c592d654615e","slug":"goals","fullItemName":"Goals"},{"id":"ac3d1637-467f-5edb-8fd8-73f66160080f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"4bffe5b2-0ce0-5ae8-8c0b-914bb6ed5a1d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"82441da5-60f5-53b4-b510-187f7bacb4a8","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3e5817d5-30e7-54b7-b9ba-224b4a295bba","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"b30bb006-efbc-5a69-90f3-30abf232a97d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"84dc0da0-8533-5c5d-99f6-7c04a116701a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"45d8d35d-9757-544c-b04e-9747898a1f0e","slug":"definition","fullItemName":"Definition"},{"id":"21acb832-e5e8-5bd1-9b8d-9410ec5011bf","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"cf27bd7b-b787-5def-bb40-ee0f134a8aca","slug":"prevalence","fullItemName":"Prevalence"},{"id":"a55a1739-f3d2-534c-b533-f6406d9c81ea","slug":"complications","fullItemName":"Complications"},{"id":"683b612a-3f1d-5580-951b-e14672f52b4a","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"dbc94220-a914-56d0-883d-d158da511e1c","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"57b3b7a5-9042-53fa-a236-56d0d02b647e","slug":"assessment","fullItemName":"Assessment"},{"id":"35ee8784-602e-5a29-9ccf-65b3c3f940d2","slug":"interpretation-of-abpi","fullItemName":"Interpretation of ABPI"},{"id":"0c766f2c-0c8f-521b-85fd-e947ba6b2d09","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"5e199f8a-7621-5318-9da1-264db8f544b8","fullItemName":"Management","slug":"management","subChapters":[{"id":"c8bda10b-ebb6-533b-9c91-96efa5ddf0c3","slug":"venous-leg-ulcers","fullItemName":"Scenario: Venous leg ulcers"}]},{"id":"e084faba-a409-53ac-aa53-08b80a3991f1","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"66a7f656-c6f5-57a2-a08a-1533a6fd4e92","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"a6cda703-9039-5115-b3d3-478cdb4d1e55","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"1cf75cbb-8bc4-58cc-9a1b-11516db5ad2c","slug":"co-trimoxazole","fullItemName":"Co-trimoxazole"},{"id":"3f0efc32-779b-56f6-85ca-e46a59745bed","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"fe306aab-d8d7-5181-a461-128f2aa3c65a","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"314a80d5-e16b-5625-8d64-4141535ff392","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"b7e7b8ec-799c-5ea5-9ac0-11935f899b8a","slug":"oral-analgesia","fullItemName":"Oral analgesia"},{"id":"43ed3b03-6322-5690-8f85-b6e10a0b3d3e","slug":"pentoxifylline","fullItemName":"Pentoxifylline"}]},{"id":"19f3ffbe-f365-5196-8586-0dceeaf69908","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"89207239-b8a4-50ce-8b2d-3065a830c0af","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"45831e7c-0e6f-50f3-a513-fe4fcacff65e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"3d90cdb0-b2fd-5bfd-bd2d-342e36901f9d","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"8b66d1a4-6ee5-5556-b671-204219a81787","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"5b8ee442-8da6-524f-bf34-e6a9cc2a771e","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6fa96be3-beae-51f6-9f1c-4d278b058d09","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e75dc366-237b-55d2-a654-2e3bf503b955","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e084faba-a409-53ac-aa53-08b80a3991f1","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"72f28eff-8252-5c4d-b9b5-cd726843aaf1","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field d7232abf-859a-4bed-b1c7-aa9000d6aabd --><h3>What are the contraindications and cautions for co-trimoxazole?</h3><!-- end field d7232abf-859a-4bed-b1c7-aa9000d6aabd -->","summary":"","htmlStringContent":"<!-- begin item 09f2fc37-6a24-4912-9f94-aa9000d6aaa3 --><!-- begin field 23722316-6e51-4116-882b-aa9000d6aabd --><ul><li><strong>Do not prescribe co-trimoxazole (trimethoprim/sulfamethoxazole) to people with:</strong><ul><li>Severe hepatic impairment.</li><li>Severe renal impairment (estimated glomerular filtration rate [eGFR] less than 15 mL/minute/1.73 m<sup>2</sup> ), unless plasma levels of co-trimoxazole can be monitored regularly.<ul><li>If plasma levels of co-trimoxazole can be monitored regularly, prescribe half the recommended <a class=\"topic-reference internal-reference\" href=\"/topics/leg-ulcer-venous/management/venous-leg-ulcers/#managing-infection\">dose</a>.</li></ul></li><li>Severe haematological disorders, such as blood dyscrasias (unless under specialist supervision).</li><li>Acute porphyria — both trimethoprim and sulfonamides (although not specifically sulfamethoxazole) have been associated with clinical exacerbation of porphyria.</li></ul></li><li><strong>Prescribe co-trimoxazole with caution </strong><strong>to:</strong><ul><li>Elderly people — increased risk of serious adverse effects, particularly when complicating conditions exist, for example renal impairment, hepatic impairment, and/or concurrent use of other drugs.</li><li>People with:<ul><li>Glucose-6-phosphate dehydrogenase deficiency — risk of haemolytic anaemia.</li><li>Severe allergy and asthma.</li><li>A predisposition to folate deficiency (for example elderly people).</li><li>Predisposition to hyperkalaemia — close monitoring of serum potassium is warranted.</li></ul></li><li>Pregnant or breastfeeding women. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/leg-ulcer-venous/prescribing-information/co-trimoxazole/#use-in-pregnancy-breastfeeding\">Use in pregnancy and breastfeeding</a> for more information.</li></ul></li><li><strong>During treatment with co-trimoxazole, an adequate urinary output should be maintained. </strong><ul><li>Evidence of crystalluria <em>in vivo </em>is rare, although sulfonamide crystals have been noted in cooled urine from people treated with co-trimoxazole. The risk may be increased in people who are malnourished.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">ABPI, 2018d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 23722316-6e51-4116-882b-aa9000d6aabd --><!-- end item 09f2fc37-6a24-4912-9f94-aa9000d6aaa3 -->","subChapters":[]},{"id":"a549e3cb-11d8-5b56-a2e3-dab380fa54fc","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 8b690d07-01fa-4df2-8ce0-aa9000d72d96 --><h3>What are the possible adverse effects of co-trimoxazole?  </h3><!-- end field 8b690d07-01fa-4df2-8ce0-aa9000d72d96 -->","summary":"","htmlStringContent":"<!-- begin item 43ebfe87-ff1d-48c8-bff5-aa9000d72d7d --><!-- begin field 76003507-5987-45e0-978f-aa9000d72d96 --><ul><li><strong>Headache, nausea, skin rashes, hyperkalaemia, fungal overgrowth, and diarrhoea</strong> are common or very common adverse effects of co-trimoxazole.<ul><li>Consider pseudomembranous colitis (an acute, exudative colitis caused by <em>Clostridium difficile</em>) if a person develops severe diarrhoea during or after treatment with co-trimoxazole. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a> for more information.</li></ul></li><li><strong>Blood disorders (including leucopenia, thrombocytopenia, anaemia, and eosinophilia)</strong> are rare but serious adverse effects of co-trimoxazole.<ul><li>Discontinue treatment with co-trimoxazole immediately if blood disorders develop.</li></ul></li><li><strong>Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS), </strong>have been rarely reported with co-trimoxazole.<ul><li>Advise people taking co-trimoxazole to monitor closely for skin reactions. The highest risk for occurrence of SJS, TEN, or DRESS is within the first weeks of treatment.</li><li>If symptoms or signs of SJS, TEN, or DRESS (for example progressive skin rash often with blisters or mucosal lesions) occur, discontinue treatment with co-trimoxazole.</li><li>If a person develops SJS or TEN with the use of co-trimoxazole, co-trimoxazole must not be re-started at any time.</li></ul></li><li><strong>Other adverse effects of co-trimoxazole include:</strong><ul><li>Uncommon — vomiting.</li><li>Rare or very rare — angioedema, arthralgia, ataxia, cough, decreased appetite, depression, dizziness, dyspnoea, fever, haemolysis, hallucination, hepatic disorders, hypoglycaemia, aseptic meningitis, metabolic acidosis, myalgia, myocarditis allergic, nephritis tubulointerstitial, pancreatitis, peripheral neuritis, photosensitivity reaction, renal impairment, renal tubular acidosis, seizure, serum sickness, systemic lupus erythematosus, tinnitus, uveitis, vasculitis, and vertigo.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">ABPI, 2018d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 76003507-5987-45e0-978f-aa9000d72d96 --><!-- end item 43ebfe87-ff1d-48c8-bff5-aa9000d72d7d -->","subChapters":[]},{"id":"52c533df-c712-5881-8fad-2b3ab5d7e99a","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field dbba26a6-f253-49fb-a676-aa9000d7ce4a --><h3>What are the possible drug interactions with co-trimoxazole?</h3><!-- end field dbba26a6-f253-49fb-a676-aa9000d7ce4a -->","summary":"","htmlStringContent":"<!-- begin item 7f9137e9-eca3-43c8-8d2d-aa9000d7ce29 --><!-- begin field 0cc30fbe-c15e-4562-a373-aa9000d7ce4a --><ul><li><strong>Interactions with co-trimoxazole (trimethoprim/sulfamethoxazole) include:</strong><ul><li><strong>Digoxin</strong> — concurrent use of trimethoprim with digoxin has been shown to increase plasma digoxin levels in some elderly people.<ul><li>If there are symptoms of digoxin toxicity (for example, nausea, anorexia, or disturbance of colour vision), check serum digoxin levels.</li><li><strong>Diuretics</strong> — in elderly people concurrently receiving diuretics, mainly thiazides, there appears to be an increased risk of thrombocytopenia with or without purpura.<ul><li>Manufacturer makes no recommendation.</li></ul></li></ul></li><li><strong>Drugs that can cause hyperkalaemia</strong> (for example angiotensin-converting enzyme [ACE] inhibitors, angiotensin receptor blockers, and diuretics) — concurrent use with co-trimoxazole may result in clinically significant hyperkalaemia. <ul><li>Concurrent use should be done cautiously. </li></ul></li><li><strong>Methotrexate</strong> — co-trimoxazole may increase free plasma levels of methotrexate. In addition, methotrexate and trimethoprim are both anti-folate drugs.<ul><li>Avoid concurrent use with co-trimoxazole.  </li><li>If co-trimoxazole treatment is necessary, a folate supplement should be considered.</li></ul></li><li><strong>Phenytoin</strong> — co-trimoxazole may prolong the half-life of phenytoin, resulting in increased serum phenytoin levels.<ul><li>If symptoms of phenytoin toxicity (confusion, blurred vision, nystagmus, ataxia, or drowsiness) are present, monitor serum phenytoin levels and reduce the dose if necessary.</li></ul></li><li><strong>Warfarin</strong> — concurrent treatment with co-trimoxazole may increase the anticoagulant effect of warfarin. <ul><li>Monitor the international normalized ratio (INR), and adjust the warfarin dose accordingly.</li></ul></li></ul></li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are not required during or after a course of co-trimoxazole [<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">FSRH, 2017</a>].<ul><li>However, advise women on the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the section on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">ABPI, 2018d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 0cc30fbe-c15e-4562-a373-aa9000d7ce4a --><!-- end item 7f9137e9-eca3-43c8-8d2d-aa9000d7ce29 -->","subChapters":[]},{"id":"2add09b3-9673-5cb8-ace9-ff0c828add7e","slug":"use-in-pregnancy-breastfeeding","fullItemName":"Use in pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field de5a0f58-dcc7-45b9-8bc3-aaa300a2ee0e --><h3>Can co-trimoxazole be used during pregnancy and breastfeeding?</h3><!-- end field de5a0f58-dcc7-45b9-8bc3-aaa300a2ee0e -->","summary":"","htmlStringContent":"<!-- begin item 624beb6f-842d-4777-9d75-aaa300a2edf1 --><!-- begin field 3c0cdd1f-8d92-4d7b-bd27-aaa300a2ee0e --><ul><li><strong>Pregnancy</strong><ul><li>The manufacturer advises that co-trimoxazole (trimethoprim/sulfamethoxazole) should not be used in pregnancy, particularly in the first trimester, unless clearly necessary. <ul><li>There is inadequate data on the use of co-trimoxazole in pregnant women. Case-control studies have shown that there may be an association between exposure to folate antagonists (such as trimethoprim) and birth defects in humans. In animal studies, trimethoprim and sulfamethoxazoleboth have been shown to cause foetal abnormalities.</li><li>Also, sulfamethoxazole competes with bilirubin for binding to plasma albumin. As significantly maternally derived drug levels persist for several days in the newborn, there may be a risk of precipitating or exacerbating neonatal hyperbilirubinaemia, with an associated theoretical risk of kernicterus, when co-trimoxazole is used in the third trimester. This theoretical risk is particularly relevant in infants at increased risk of hyperbilirubinaemia, such as those who are preterm and those with glucose-6-phosphate dehydrogenase deficiency.</li></ul></li></ul></li><li><strong>Breastfeeding</strong><ul><li>Co-trimoxazole passes into breast milk.</li><li>The manufacturer advises that co-trimoxazole should be avoided during breastfeeding if the mother or infant has, or is at particular risk of developing, hyperbilirubinaemia. </li><li>There is a small risk of kernicterus in jaundiced infants, and of haemolysis in G6PD-deficient infants (due to sulfamethoxazole).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">ABPI, 2018d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 3c0cdd1f-8d92-4d7b-bd27-aaa300a2ee0e --><!-- end item 624beb6f-842d-4777-9d75-aaa300a2edf1 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}